SILO PHARMA, INC. Management Fee Expense
SILO PHARMA, INC. (SILO) had Management Fee Expense of $187.50 thousand as of 2025-09-29, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:ManagementFeeExpense · last filed 2026-08-13
- 2025-09-29: Management Fee Expense $187.50K.
- 2025-05-06: Management Fee Expense $187.50K.
- 2024-06-04: Management Fee Expense $170.00K.
- 2024-04-23: Management Fee Expense $170.00K.
| Period end | Management Fee Expense |
|---|---|
| 2025-09-29 | $187.50K 10-Q · filed 2026-08-13 |
| 2025-05-06 | $187.50K 10-Q · filed 2026-08-13 |
| 2024-06-04 | $170.00K 10-Q · filed 2024-08-13 |
| 2024-04-23 | $170.00K POS AM · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |